(Q34522201)

2 August 2017

title

Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. (English)

1 reference

cytomegalovirus retinitis

2 August 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Vitravene Study Group.

series ordinal

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

American Journal of Ophthalmology

2 August 2017

published in

1 reference

2 August 2017

volume

133

1 reference

2 August 2017

1 reference

2 August 2017

page(s)

484-498

1 reference

Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Treatment of cytomegalovirus retinitis with ganciclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

A Randomized, Controlled Trial of Foscarnet in the Treatment of Cytomegalovirus Retinitis in Patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Cli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Complications after implantation of intraocular devices in patients with cytomegalovirus retinitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Outcomes of cytomegalovirus retinitis following the use of ganciclovir implants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

High-dose (2000-microgram) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Ocular complications of intravenous cidofovir for cytomegalovirus retinitis in patients with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Intraocular Pressure and Aqueous Humor Dynamics in Patients With AIDS Treated With Intravitreal Cidofovir (HPMPC) for Cytomegalovirus Retinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

7 January 2021

Immune recovery uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

[Bilateral cystoid macular edema after successful treatment of AIDS-associated cytomegalovirus retinitis]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Decreased visual acuity in patients with cytomegalovirus retinitis and AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Cytomegalovirus retinitis in the era of highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Effect of antisense oligonucleotides on cytokine release from human keratinocytes in an in vitro model of skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

The antisense oligonucleotide ISIS 2922 prevents cytomegalovirus-induced upregulation of IL-8 and ICAM-1 in cultured human fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

The role of CpG motifs in innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Retinal pigment epithelial dysfunction in human immunodeficiency virus-infected patients with cytomegalovirus retinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Local Therapy for Cytomegalovirus Retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

Management of cytomegalovirus disease with antiviral drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Retinal Toxicity in Human Immunodeficiency Virus–infected Children Treated With 2′,3′-Dideoxyinosine

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901332-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9394(02)01332-6

1 reference

2 August 2017

1 reference